Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The FKBP12–CEP250 ternary complex is a chemically induced protein-protein interaction formed by the recruitment of the cytosolic chaperone FKBP12 (Peptidyl-prolyl cis-trans isomerase FKBP1A) to the centrosomal protein 250 (CEP250, also known as C-Nap1) via a molecular glue (PNAS, 2020; NIH.gov). This interaction was first characterized using the natural product WDB002, which binds to the topologically flat coiled-coil domain of CEP250, a surface previously considered undruggable by conventional small molecules (ResearchGate, 2020). Biologically, the formation of this complex disrupts the normal function of CEP250 in maintaining centrosome cohesion, thereby interfering with NEK2-mediated centrosome separation during the cell cycle (Arxiv.org, 2025). This mechanism has therapeutic potential in oncology, where centrosome disruption can lead to cell cycle arrest or apoptosis in cancer cells (Revmed.com, 2020). Additionally, the complex has been explored for antiviral applications, as CEP250 is a known host interactor for the SARS-CoV-2 Nsp13 protein (RCSB.org, 2020). The discovery of this complex highlights the genetically programmable nature of FKBP12-mediated recognition, allowing small molecules to reprogram the chaperone to target diverse, previously inaccessible proteins (PNAS, 2020).
Molecular glue-induced proximity leading to disruption of centrosome cohesion and inhibition of NEK2-mediated centrosome separation
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptidyl-prolyl cis-trans isomerase FKBP1A–Centrosomal protein of 250 kDa ternary complex (FKBP12–CEP250 complex).